GlassScriptPhysician profile
Amanda B Paul
NPI 1912259755
$965.01
in general payments reported to CMS, 2019-2025
14 companies · $290 in 2025
The $290 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.24 · 2023: $23.36 · 2024: $633 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $946.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $340.64 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $157.89 | 2025 | Airsupra |
| Abbvie INC. | $107.38 | 2023-2025 | |
| Almatica Pharma LLC | $79.73 | 2024 | Loreev Xr |
| Pfizer INC. | $49.61 | 2024 | |
| Astellas Pharma US INC | $37.71 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $33.11 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $28.70 | 2024 | Mounjaro, Zepbound |
| Biogen, INC. | $25.37 | 2024 | Skyclarys |
| Noven Therapeutics, LLC | $24.01 | 2024 | Xelstrym |
| Neos Therapeutics, LP | $23.56 | 2024 | Adzenys Xr-Odt |
| Tris Pharma INC | $21.03 | 2024 | Dyanavel Xr |
| Grifols USA, LLC | $18.24 | 2021 | |
| Ibsa Pharma INC. | $18.03 | 2025 | Flector, Licart, Tirosint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Paul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.